Presently, there is an ongoing clinical trial testing the effectiveness of anti-MAGE-A3/12 in TCR-gene engineered lymphocytes in metastatic cancer patients (NCT01273181). The gene discussed is MAGEA3; the disease is metastatic malignant neoplasm.